PD-1/PD-L1信号通路与慢性乙型肝炎*

doi:10.3969/j.issn.1672-5069.2014.06.028

摘要/Abstract

摘要： 目的程序性死亡分子-1（programmed death-1,PD-1）是近年来发现的属于B7/CD28家族的重要协同刺激分子,与其配体（programmed death -1 ligand,PD-L）结合后在调节T淋巴细胞的活化、分化及增殖功能方面起着重要作用。在慢性HBV感染不同阶段,PD-1表达水平存在差异,且与肝脏炎症程度、ALT及病毒载量等密切相关。通过不同途径阻断PD-1/PD-L1通路可以使耗竭的T淋巴细胞功能得到改善,提示可能是未来抗病毒治疗的方向之一。

关键词: 慢性乙型肝炎, 程序性死亡分子-1, 程序性死亡分子-1配体, T淋巴细胞

Abstract: Programmed death-1（PD-1） is an important coordinated stimulus molecule belonging to the B7/CD28 family. When it combines with its ligand programmed death ligand （PD-L）,can regulate the activation,differentiation and multiplication of T lymphocytes. PD-1 expression in different stages of chronic HBV infection varies,and is closely related to the degree of liver inflammation,ALT levels and viral loads. Through different ways to block the PD-1/PD-L1 pathway can improve the function of T lymphocytes,and it might be one of the direction for antiretroviral treatment in the future.

Key words: Hepatitis B, Programmed death-1, Programmed death -1 ligand, T lymphocytes

万和荷综述, 刘丽丽, 侯勇, 张国梁审校. PD-1/PD-L1信号通路与慢性乙型肝炎^*[J]. 实用肝脏病杂志, 2014, 17(6): 661-665.

Wan Hehe, Liu Lili, Hou Yong, Zhang Guoliang. PD-1/PD-L signal pathway in chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 661-665.

参考文献

[1] Chen GC,Yu T,Huang KH,et al. Antiviral therapy of decompensated hepatitis B virus-related cirrhosis. Chin Med J,2012,125（2）:373-377.
[2] Li XD,Wang L,Liu Y,et al. Characterization of hepatitis B virus genotypes/subgenotypes in 1301 patients with chronic hepatitis B in North China. Chin Med J,2011,124（24）:4178-4183.
[3] Lok AS,McMahon BJ. Chronic hepatitis B. Hepatology,2007,45（2）:507-539.
[4] Yao S,Chen L. Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade. Trends Mol Med,2006,12（6）:244-246.
[5] Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol,2004,4（5）:336-347.
[6] Ishida Y,Agata Y,Shibahara K,et al. Induced expression of PD1,a novel member of the immunoglobulin gene superfamily upon programmed cell death. EMBO J,1992,11（11）:3887-3895.
[7] Greenwald RJ,Freeman GJ,Sharpe AH. The B7 family revisited. Annu Rev Immunol,2005,23:515-548.
[8] Bennett F,Luxenberg D,Ling V,et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation:attenuation of ICOS,IL-4,and IL-21,but not CD28,IL-7,and IL-15 responses. J Immunol,2003,170（2）:711-718.
[9] Okazaki T,Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol,2006,27（4）:195-201.
[10] Wherry EJ,Ha SJ,Kaech SM,et al. Molecular signature of CD8 + T cell exhaustion during chronic viral infection. Immunity,2007,27（4）:670-684.
[11] Boni C,Fisicaro P,Valdatta C,et al. Characterization of hepatitis B virus （HBV）-specific T-cell dysfunction in chronic HBV infection. J Virol,2007,81（8）: 4215-4225.
[12] Nishimura H,Honjo T,Minato N. Facilitation of beta selection and modification of positive selection in the thymus of PD-l-deficient mice. J Exp Med,2000,191（5）:891-898.
[13] Zhang X,Schwartz JC,Guo XL,et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity,2004,20（3）:337-347.
[14] Yang W,Li H,Chen PW,et al. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthmol Vis Sci,2009,50（1）:273-280.
[15] Fife BT,Pauken KE. The role of the PD1 pathway in autoimmunity and peripheral tolerance. Ann NY Acad Sci,2011,1217:45-59.
[16] Sugita S,Usui Y,Horie S,et al. Human corneal endothelial cells expressing programmed death-ligand l（PD-Ll） suppress PD-l+ T helper 1 cells by a contact-dependent mechanism. Invest Ophthalmol Vis Sci,2009,50（l）:263-272.
[17] Margarite L,Tarrio N,Grabie N,et al. PD-1 protects against inflammation and lymphocyte damage in T cell mediated myocarditis. J Immunol,2012,188（10）:4876-4884.
[18] Liang SC,Latchman YE,Buhlmann JE,et al. Regulation of PD-1,PD-L1 and PD-L2 expression during normal and autoimmune responses. Eur J Immunol,2003,33（10）:2706-2716.
[19] Ishida M,Iwai Y,Tanaka Y,et al. Differential expression of PD-L1 and PD-L2,ligands for an inhibitory receptor PD-1,in the cells of lymphohematopoietic tissues. Immunol Lett,2002,84（1）:57-62.
[20] Martinic MM,Von Herrath MG. Novel strategies to eliminate persistent viral infections. Trends Immunol,2008,29（3）:116-124.
[21] Sakuishi K,Apetoh L,Sullivan JM,et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med,2010,207（10）:2187-2194.
[22] Baecher-Allan C,Brown JA,Freeman GJ,et al. CD4 + CD25 + regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp,2003,252:67-68.
[23] Grzywnowicz M,Zaleska J,Mertens D,et al. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One,2012,7（4）:e35178.
[24] Tamura H,Dong HD,Zhu GF. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood,2001,97（6）:1809-1816.
[25] Zhang Z,Jin B,Zhang JY,et al. Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients. J Hepatol,2009,50:1163-1173.
[26] Ye P,Weng ZH,Zhang SL,et al. Programmed death-1 expression is associated with the disease status in hepatitis B virus infection. World J Gastroenterol,2008,14:4551-4557.
[27] Peng G,Li S,Wu W,et al. PD-1 upregulation is associated with HBV- specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol,2008,45（4）:963-970.
[28] Fisicaro P,Valdatta C,Massari M,et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology,2010,138（2）:682-693.
[29] 梁雪松,李成忠,万漠彬,等. 外周血T细胞表面PD-1在慢性乙型肝炎患者干扰素治疗期间的表达. 世界华人消化杂志,2009,17:2899-2902.
[30] Zhang WJ,Peng CH,Zheng SS. Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int,2013,12（4）:394-399.
[31] Liang XS,Zhou Y,Li CZ,et al. Natural course of chronic hepatitis B is characterized by changing patterns of programmed death type-1 of CD8-positive T cells. World J Gastroenterol,2010,16（5）:618-624.
[32] 李新慧,夏娟,许林,等. 慢性乙型肝炎患者不同免疫状态下外周血T细胞表面程序性死亡受体1的表达. 江苏医药,2011,7（12）:1423-1426.
[33] Tzeng HT,Tsai HF,Liao HJ,et al. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model[J/OA]. PLoS One,2012,7（6）:e39179.
[34] Xie Z,Chen Y,Zhao S,et al. Intrahepatic PD-1/PD-Ll up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection. Immunol Invest,2009,38（7）:624-638.
[35] Georgios G,Nikoletta A,Prodromos H,et al. Liver FOXP3 and PD1/PDL1 expression is down-regulated in chronic HBV hepatitis on maintained remission related to the degree of inflammation. Frontiers in Immunol,2013,4:1-9.dol:10.3389/fimmu.2013.00207.
[36] Ping X,Yong JC,Hui C,et al. The expression of programmed death-1 in circulating CD4 + and CD8 + T cells during hepatitis B virus infection progression and its correlation with clinical baseline characteristics. Gut Liver,2014,8（2）:186-195.
[37] 谢冬英,陈凤娟,林炳亮,等. PD-1和PD-L1表达与慢性HBV感染者肝脏病变程度的相关性. 中华实验和临床感染病杂志:电子版,2010,4（3）:287-293.
[38] 叶翩,翁志宏,张淑玲,等.慢性乙型肝炎患者外周血CD8+T淋巴细胞表面程序性死亡受体-1表达上调的意义.中华肝脏病杂志,2008,16 （9）:706-707.
[39] Ghiotto M,Gauthier L,Serriari N,et al. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol,2010,22（8）: 651-660.
[40] Evans A,Riva A,Cooksley H,et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B:Impact of hepatitis B e-antigen seroconversion. Hepatology,2008,48:759-769.
[41] Bowen DG,Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature,2005,436:946-952.
[42] Chen LG,Zhang Z,Chen WW,et al. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol,2007,178 （10）:6634.
[43] Maier H,Isogawa M,Freeman GJ,et al. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol,2007,178（5）:2714-2720.

PD-1/PD-L1信号通路与慢性乙型肝炎^*

PD-1/PD-L signal pathway in chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[6]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[7]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[8]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[9]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[10]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[11]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[12]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[13]	闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.
[14]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.
[15]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.